文献速递系统性红斑狼疮

系统性红斑狼疮患者的健康相关生活质量、缓解与狼疮低疾病活动状态

Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该前瞻性队列研究纳入336例系统性红斑狼疮(SLE)患者,随访2年,采用LupusPRO、LupusQoL、SLEQOL和SF-36问卷评估患者报告结局(PRO)。混合模型分析显示,缓解期用药(RONT)、停药缓解(ROFT)和狼疮低疾病活动状态(LLDAS)与LupusPRO(疾病特异性)和SF-36(通用)多数领域临床相关的生活质量升高相关,但LupusQoL和SLEQOL各领域均未达到至少5分的组间差异。

要点

  • 在LupusPRO中,LLDAS、RONT和ROFT与狼疮症状、狼疮药物、疼痛活力领域评分较无缓解/无LLDAS组至少高5分相关。
  • 在SF-36中,RONT与角色情感、角色躯体、躯体疼痛、心理健康、社会功能领域至少高5分相关,ROFT与角色躯体至少高5分相关。
  • LupusQoL和SLEQOL所有领域均未达到至少5分的组间差异。

核心结论

  • RONT、ROFT和LLDAS与LupusPRO(疾病特异性)和SF-36(通用)问卷多数领域显著且临床相关的生活质量升高相关,但与LupusQoL和SLEQOL疾病特异性问卷无关。

研究设计与样本

  • 前瞻性队列研究,纳入336例SLE患者,随访2年,共收集1478次医疗访视和2547份PRO问卷。
  • 使用LupusPRO、LupusQoL、SLEQOL和SF-36问卷评估患者报告结局。
  • 缓解定义为停药缓解(ROFT)和用药缓解(RONT),依据SLE缓解共识定义;采用混合模型比较ROFT和RONT vs 无缓解、LLDAS vs 无LLDAS。

主要发现

  • LupusPRO领域组间差异达至少5分(0-100量表):狼疮症状LLDAS +5分、RONT +9分、ROFT +5分;狼疮药物LLDAS +5分、RONT +8分、ROFT +9分;疼痛活力LLDAS +6分、RONT +9分、ROFT +6分。
  • SF-36领域组间差异达至少5分:角色情感LLDAS +5分、RONT +8分;角色躯体RONT +7分、ROFT +7分;躯体疼痛RONT +6分;心理健康RONT +5分;社会功能RONT +6分。
  • LupusQoL和SLEQOL所有领域均未达到至少5分的组间差异。

关键数值与推荐

  • 缓解定义采用SLE缓解共识中的ROFT和RONT定义。
  • 组间PRO评分差异以0-100量表上至少5分作为临床相关阈值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To measure the association between SLE remission and scores of patients-reported outcome (PRO) measures. METHODS: We performed a prospective cohort study of SLE patients with a 2-year follow-up, using Lupus Patient-Reported Outcome (LupusPRO), Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus Quality of Life (SLEQOL) and 36-item Short Form (SF-36) questionnaires. Remission was defined as remission off treatment (ROFT) and remission on treatment (RONT) according to the definitions of remission in SLE consensus. Mixed models accounting for repeated measures were used to compare groups as follow: ROFT and RONT vs no remission and lupus low disease activity state (LLDAS) vs no LLDAS. RESULTS: A total of 1478 medical visits and 2547 PRO questionnaires were collected during the follow-up from the 336 recruited patients. A between-group difference in PRO scores reaching at least 5 points on a 0-100 scale was obtained in the following domains: lupus symptoms (LLDAS: +5 points on the 0-100 scale, RONT: +9, ROFT: +5), lupus medication (LLDAS: +5, RONT: +8, ROFT: +9), pain vitality (LLDAS: +6, RONT: +9, ROFT: +6) of LupusPRO; role emotional (LLDAS: +5, RONT: +8), role physical (RONT: +7 and ROFT: +7), bodily pain (RONT: +6), mental health (RONT: +5) and social functioning (RONT: +6) of SF-36. In contrast, a between-group difference reaching at least 5 points was not achieved for any of the LupusQoL and SLEQOL domains. CONCLUSIONS: RONT, ROFT and LLDAS were associated with significant and clinically relevant higher QoL in most PRO domains of the LupusPRO (disease specific) and SF-36 (generic) questionnaires, but not with LupusQoL and SLEQOL disease-specific questionnaires.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Thibault T, Rajillah A, Bourredjem A, et al. Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2024. PMID: 37589711. doi:10.1093/rheumatology/kead407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。